(Reuters) - But the European Medicines Agency stopped short of suspending the medicine and said the benefits of Acomplia continued to outweigh its risks, except in patients with ongoing major depression or taking antidepressants.
The drug should be contra-indicated for this group of patients, it said.
Read more at Reuters.com Government Filings News
The drug should be contra-indicated for this group of patients, it said.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment